<DOC>
	<DOCNO>NCT01271088</DOCNO>
	<brief_summary>Peritonitis currently one lead complication continuous ambulatory peritoneal dialysis ( CAPD ) . Aminoglycosides vancomycin use treatment CAPD peritonitis despite potential risk ototoxicity . NAC molecule use treatment prophylaxis many disease related oxidative stress . The aim study examine whether ototoxicity due antibiotic use treatment CAPD peritonitis prevent N-acetylcysteine</brief_summary>
	<brief_title>Protective Effect N-acetylcysteine Against From Ototoxicity</brief_title>
	<detailed_description>NAC , thiol-containing antioxidant , want investigate antioxidant status .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Endstage renal disease Undergoing continuous ambulatory peritoneal dialysis renal replacement therapy Developing first continuous ambulatory peritoneal dialysis relate peritonitis episode Being treat aminoglycoside antibiotic vancomycine within previous 3 month Detection mechanical occlusion external ear Having sign disturb integrity tympanic membrane otoscopy tympanometry History continuous ambulatory peritoneal dialysis relate peritonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ototoxicity</keyword>
	<keyword>aminoglycoside</keyword>
	<keyword>vancomycine</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>peritonitis</keyword>
</DOC>